Loading
TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.
Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells.
IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Oesophageal Squamous Cell Carcinoma. In OnCo, 2 product records name it (Ibrutinib and Acalabrutinib).
In plain words · TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.
TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.
Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton.
No product in this corpus aims at TEC yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 2 medicines aimed at it (Acalabrutinib, Ibrutinib) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA TEC: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 21 nTPM); high antibody staining in 10 normal tissues; highest cancer staining lymphoma (9 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Oesophageal cancer); approvals of single-target medicines aimed at it also list Leukaemia, Lymphoma, not counted; Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas TEC tissue; Open Targets ENSG00000135605 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Sato et al, Leukemia, 1994, "Molecular cloning and analysis of the human Tec protein-tyrosine kinase". Source.
Sources: HGNC HGNC:11719 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42680 (protein name, function text, keywords and locations (REST API)); IntOGen TEC (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Non-receptor tyrosine kinase that contributes to signalling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. Required for TCR-dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific substrate, and contributes to CD28-signalling. Mediates signals that negatively regulate IL2RA expression induced by TCR cross-linking. Location: Cytoplasm; Cell membrane; Cytoplasm, cytoskeleton (UniProt). Locus 4p12-p11 (HGNC).
RNA: low tissue specificity, detected in many normal tissues. Blood: lineage enriched (granulocytes 21 nTPM).
Medium: Breast, Caudate, Cerebellum, Cerebral cortex, Endometrium, Fallopian tube, Gallbladder, Heart muscle.
Medium only: head and neck cancer, melanoma, renal cancer, testis cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TEC" OR ABSTRACT:"TEC" OR TITLE:"tec protein tyrosine kinase" OR ABSTRACT:"tec protein tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Tec" OR ABSTRACT:"Tyrosine-protein kinase Tec" OR TITLE:"PSCTK4" OR ABSTRACT:"PSCTK4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TEC, not a curated reading list.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
Shares Acalabrutinib, Ibrutinib.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.